Optune

From Glioblastoma Treatments
Revision as of 06:10, 29 March 2024 by Lazy (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigationJump to search
Property Information
Drug Name Optune (Optune Gio® for newer version)
FDA Approval Approved for newly diagnosed glioblastoma in October 2015; ongoing trials for broader applications
Used for Newly diagnosed glioblastoma, with trials for other cancers ongoing
Clinical Trial Phase Phase 3 (EF-14 Trial); Phase 3 TRIDENT trial ongoing
Clinical Trial Explanation Not specified
Common Side Effects Mild to moderate skin irritation beneath transducer arrays, thrombocytopenia, nausea, constipation, vomiting, fatigue, headache, convulsions, depression
OS without 16 months (control group in EF-14 Trial)
OS with 20.9 months (Optune plus temozolomide, final EF-14 analysis)
PFS without 4 months (control group in EF-14 Trial)
PFS with 7.1 months (Optune arm in EF-14 Trial); 6.7 months from diagnosis in updated analysis
Usefulness Rating 5
Usefulness Explanation Not specified
Toxicity Level 2
Toxicity Explanation Most common adverse reaction is skin irritation at the device contact points; no increase in systemic adverse events

Notes: Optune's significance is underscored by its addition to standard care for glioblastoma, showing remarkable survival benefits. It exemplifies the potential for non-invasive therapies in treating aggressive cancers, suggesting a paradigm shift in oncological treatments.


From Ben Williams Book: Optune, now including Optune Gio® as its latest version, has shown significant survival benefits for newly diagnosed glioblastoma patients, especially when used in combination with temozolomide. It has been a part of a landmark phase 3 trial (EF-14) that demonstrated a considerable extension in both overall survival and progression-free survival. An ongoing TRIDENT trial is further investigating its efficacy in conjunction with radiation therapy and temozolomide from the onset of treatment. Optune represents a shift towards non-invasive cancer treatment modalities with reduced systemic toxicity and improved quality of life for patients.Property "Has original text" (as page type) with input value "Optune, now including Optune Gio® as its latest version, has shown significant survival benefits for newly diagnosed glioblastoma patients, especially when used in combination with temozolomide. It has been a part of a landmark phase 3 trial (EF-14) that demonstrated a considerable extension in both overall survival and progression-free survival. An ongoing TRIDENT trial is further investigating its efficacy in conjunction with radiation therapy and temozolomide from the onset of treatment. Optune represents a shift towards non-invasive cancer treatment modalities with reduced systemic toxicity and improved quality of life for patients." contains invalid characters or is incomplete and therefore can cause unexpected results during a query or annotation process.

Loading comments...